Literature DB >> 25111255

Immunomodulatory agents for the treatment of cachexia.

Martin Chasen1, Ravi Bhargava, Shalom Hirschman.   

Abstract

PURPOSE OF REVIEW: In patients with advanced cancer, AIDS and end-stage organ diseases, symptoms of cachexia syndrome include decrease in appetite, weight loss, decreased performance status, and an increase in the systemic inflammatory response. Inflammatory cytokines and other immune interactions affect the lean tissue mass and body fat. It is hopeful that modulation of these inflammatory interactions may contribute to the delay in the development and treatment of cachexia. This review summarizes the current state of the art. RECENT
FINDINGS: This article covers the role of inflammatory response in cachexia, measurement of inflammatory response, mechanism and measurement of cachexia, immunomodulation in cancer, drugs targeting inflammatory cytokines, effect of exercise in cachexia, and treatment of cancer cachexia using immunomodulatory agents.
SUMMARY: Understanding the immune response associated with cachexia may improve future pharmacological modification of the cytokines. In addition, the multifactorial contributions to the mechanisms of cachexia indicate that a multimodal approach may be necessary to treat cachexia and its associated symptoms.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25111255     DOI: 10.1097/SPC.0000000000000086

Source DB:  PubMed          Journal:  Curr Opin Support Palliat Care        ISSN: 1751-4258            Impact factor:   2.302


  2 in total

1.  Tumour inflammatory response: adding fuel to the fire?

Authors:  M Valdes; M R Chasen
Journal:  Curr Oncol       Date:  2015-02       Impact factor: 3.677

Review 2.  Metastasis and cachexia: alongside in clinics, but not so in animal models.

Authors:  Rebeka Tomasin; Ana Carolina Baptista Moreno Martin; Márcia Regina Cominetti
Journal:  J Cachexia Sarcopenia Muscle       Date:  2019-08-22       Impact factor: 12.910

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.